203 related articles for article (PubMed ID: 35448172)
1. Implication of ERBB2 as a Predictive Tool for Survival in Patients with Pancreatic Cancer in Histological Studies.
Ortega MA; Pekarek L; Fraile-Martinez O; Garcia-Montero C; Saez MA; Asúnsolo A; Alvarez-Mon MA; Monserrat J; Ruiz-Llorente L; García-Honduvilla N; Albillos A; Buján J; Alvarez-Mon M; Guijarro LG
Curr Oncol; 2022 Mar; 29(4):2442-2453. PubMed ID: 35448172
[TBL] [Abstract][Full Text] [Related]
2. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
3. Towards an updated view on the clinical management of pancreatic adenocarcinoma: Current and future perspectives.
Pekarek L; Fraile-Martinez O; Garcia-Montero C; Alvarez-Mon MA; Acero J; Ruiz-Llorente L; García-Honduvilla N; Albillos A; Buján J; Alvarez-Mon M; Guijarro LG; Ortega MA
Oncol Lett; 2021 Nov; 22(5):809. PubMed ID: 34630716
[TBL] [Abstract][Full Text] [Related]
4. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future.
Christenson ES; Jaffee E; Azad NS
Lancet Oncol; 2020 Mar; 21(3):e135-e145. PubMed ID: 32135117
[TBL] [Abstract][Full Text] [Related]
5. Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast.
Lee A; Park WC; Yim HW; Lee MA; Park G; Lee KY
Jpn J Clin Oncol; 2007 Sep; 37(9):708-14. PubMed ID: 17940078
[TBL] [Abstract][Full Text] [Related]
6. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma.
Kawesha A; Ghaneh P; Andrén-Sandberg A; Ograed D; Skar R; Dawiskiba S; Evans JD; Campbell F; Lemoine N; Neoptolemos JP
Int J Cancer; 2000 Nov; 89(6):469-74. PubMed ID: 11102889
[TBL] [Abstract][Full Text] [Related]
7. Unraveling ERBB network dynamics upon betacellulin signaling in pancreatic ductal adenocarcinoma in mice.
Hedegger K; Algül H; Lesina M; Blutke A; Schmid RM; Schneider MR; Dahlhoff M
Mol Oncol; 2020 Aug; 14(8):1653-1669. PubMed ID: 32335999
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel predictive markers for the prognosis of pancreatic ductal adenocarcinoma.
Luo Y; Qiu Z; Tian L; Zhu G; Feng Y; Yi M; Chen X; Wang L; Li C; Huang Q
Hum Pathol; 2013 Jan; 44(1):69-76. PubMed ID: 22939953
[TBL] [Abstract][Full Text] [Related]
9. Cyclin D1, p16(INK) (4A) and p27(Kip1) in pancreatic adenocarcinoma: assessing prognostic implications through quantitative image analysis.
Georgiadou D; Sergentanis TN; Sakellariou S; Filippakis GM; Zagouri F; Vlachodimitropoulos D; Psaltopoulou T; Lazaris AC; Patsouris E; Zografos GC
APMIS; 2014 Dec; 122(12):1230-9. PubMed ID: 25053516
[TBL] [Abstract][Full Text] [Related]
10. The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells.
Momeny M; Esmaeili F; Hamzehlou S; Yousefi H; Javadikooshesh S; Vahdatirad V; Alishahi Z; Mousavipak SH; Bashash D; Dehpour AR; Tavangar SM; Tavakkoly-Bazzaz J; Haddad P; Kordbacheh F; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Cell Oncol (Dordr); 2019 Aug; 42(4):491-504. PubMed ID: 31025257
[TBL] [Abstract][Full Text] [Related]
11. Diverse and precision therapies open new horizons for patients with advanced pancreatic ductal adenocarcinoma.
Bai RL; Wang NY; Zhao LL; Zhang YF; Cui JW
Hepatobiliary Pancreat Dis Int; 2022 Feb; 21(1):10-24. PubMed ID: 34538570
[TBL] [Abstract][Full Text] [Related]
12. Cyclin D1 is a strong prognostic factor for survival in pancreatic cancer: analysis of CD G870A polymorphism, FISH and immunohistochemistry.
Bachmann K; Neumann A; Hinsch A; Nentwich MF; El Gammal AT; Vashist Y; Perez D; Bockhorn M; Izbicki JR; Mann O
J Surg Oncol; 2015 Mar; 111(3):316-23. PubMed ID: 25470788
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study.
Langer R; Von Rahden BH; Nahrig J; Von Weyhern C; Reiter R; Feith M; Stein HJ; Siewert JR; Höfler H; Sarbia M
J Clin Pathol; 2006 Jun; 59(6):631-4. PubMed ID: 16731604
[TBL] [Abstract][Full Text] [Related]
15. Differential impact of the ERBB receptors EGFR and ERBB2 on the initiation of precursor lesions of pancreatic ductal adenocarcinoma.
Meyers N; Gérard C; Lemaigre FP; Jacquemin P
Sci Rep; 2020 Mar; 10(1):5241. PubMed ID: 32251323
[TBL] [Abstract][Full Text] [Related]
16. Reduced membranous and ectopic cytoplasmic expression of beta -catenin correlate with cyclin D1 overexpression and poor prognosis in pancreatic cancer.
Qiao Q; Ramadani M; Gansauge S; Gansauge F; Leder G; Beger HG
Int J Cancer; 2001 May; 95(3):194-7. PubMed ID: 11307154
[TBL] [Abstract][Full Text] [Related]
17. Evolution of Systemic Therapy in Metastatic Pancreatic Ductal Adenocarcinoma.
Kamgar M; Chakrabarti S; Shreenivas A; George B
Surg Oncol Clin N Am; 2021 Oct; 30(4):673-691. PubMed ID: 34511189
[TBL] [Abstract][Full Text] [Related]
18. Net expression inhibits the growth of pancreatic ductal adenocarcinoma cell PL45 in vitro and in vivo.
Li B; Wan X; Zhu Q; Li L; Zeng Y; Hu D; Qian Y; Lu L; Wang X; Meng X
PLoS One; 2013; 8(2):e57818. PubMed ID: 23469073
[TBL] [Abstract][Full Text] [Related]
19. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
20. Pancreas adenocarcinoma: novel therapeutics.
Krantz BA; Yu KH; O'Reilly EM
Chin Clin Oncol; 2017 Jun; 6(3):30. PubMed ID: 28705007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
